Source: Gordon Thompson
Jefferies’ Dennis Ding Sets $30 Price Target for NASDAQ:MLYS
On March 13, 2026, Dennis Ding, a financial analyst from Jefferies, set a price target of $30 for Mineralys Therapeutics, Inc. (NASDAQ:MLYS), indicating a potential upside of approximately 14.37%. At the time, MLYS was trading at $26.23, suggesting that there is significant room for growth within this stock. This optimistic outlook from Jefferies reflects a vote of confidence in the company’s future performance and growth potential.
Jefferies is a globally renowned investment banking firm, and its guidance is often taken into account by investors worldwide. Thus, the set price target carries substantial weight in the financial market and can influence investor sentiment towards Mineralys Therapeutics.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., listed on NASDAQ under the ticker symbol MLYS, is a biopharmaceutical company that focuses on the development of innovative therapies for cardiovascular and renal diseases. The company is dedicated to meeting unmet medical needs through its advanced research and development efforts. Operating within the competitive landscape of the pharmaceutical sector, Mineralys Therapeutics aims to bring effective treatments to market, thereby challenging other companies in the same space.
MLYS’s Q4 2025 Earnings Call Highlights
Recently, MLYS held its Q4 2025 earnings call, which revealed significant developments and strategic growth plans. This information is vital for investors and stakeholders interested in the company’s growth trajectory. During this call, as reported by Seeking Alpha, the company provided valuable insights into its financial performance and strategic initiatives. The detailed financial analysis given during this call is a useful tool for investors looking to understand the company’s operations better and make informed decisions about their investment strategies.
Volatility of MLYS Stock
The stock of MLYS has experienced significant volatility over the past year. It has reached a yearly high of $47.65 and a low of $10.44, indicating substantial price fluctuations. Currently, MLYS is priced at $26.19, reflecting a decrease of 2.96% with a drop of $0.80. The stock’s price has also fluctuated during intraday trading, with a low of $25.45 and a high of $28.65. Such volatility can be attractive to certain types of investors, especially those who are comfortable with higher risk for potentially higher returns.
Market Capitalization and Trading Volume
Mineralys Therapeutics’ market capitalization stands at approximately $1.74 billion, reflecting its size and market presence. Market capitalization is a key indicator of a company’s value and is often used by investors to compare companies of similar sizes. The company’s substantial market cap signifies its substantial stakeholder base and its ability to generate revenue and profits.
Furthermore, the trading volume for MLYS on the NASDAQ today is 1,380,806 shares, indicating active investor interest and engagement with the stock. Trading volume is an essential factor investors consider as it provides insights into the stock’s liquidity and the market’s perception of the stock’s value. High trading volumes can often indicate a strong investor interest and can lead to more price volatility.
Conclusion
With the latest price target set by Jefferies and the insights from the recent earnings call, MLYS appears to be on a promising path. However, the stock’s significant volatility suggests that potential investors should approach with a degree of caution. As always, individual investors should conduct thorough research or consult a financial advisor before making any investment decisions.